Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer

ClinicalTrials.gov ID: NCT00041639

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00041639. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/II Study of Radioimmunotherapy With 90Y-Humanized MN-14 IgG Administered as a Single Dose to Patients With Refractory Advanced/Metastatic Pancreatic Carcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this trial is to determine the safety of 90Y-hMN14 at different dose levels in the treatment of pancreatic cancer.

Study identification

NCT ID: NCT00041639
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Gilead Sciences; Industry
Enrollment: 75 participants

Conditions and interventions

Conditions

Pancreatic Neoplasms

Interventions

hMN14 (labetuzumab) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 2000 (Type not available)
Primary completion: Not listed
Completion: Dec 2003 (Type not available)
Last update posted: Aug 19, 2021

2000 – 2003

United States locations

U.S. sites: 5
U.S. states: 5
U.S. cities: 5

Facility	City	State	ZIP	Site status
Hoag Cancer Center	Newport Beach	California	92658	—
Washington Hospital Center	Washington D.C.	District of Columbia	20010	—
Bay Pines VA Medical Center	St. Petersburg	Florida	33744	—
University of Pittsburgh Cancer Institute	Pittsburgh	Pennsylvania	15213	—
Virginia Mason Medical Center	Seattle	Washington	98101-2799	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00041639, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 19, 2021 · Synced Nov 12, 2026